Accelerating Complex Biomarkers, Novel & Multimodal Endpoints to Fuel Drug-Diagnostic Innovations from Bench-to-Bedside for Global Precision Medicine Access
With the FDA’s LDT and 510(k) regulatory recalibration now easing long-standing hesitation and bottlenecks in drug diagnostic approvals, we are entering a defining new chapter for precision medicine. What began as tentative regulatory shifts in mid-2025 has now reshaped the entire translational, clinical, and commercial landscape: accelerated synchronized Rx-Dx launches, the rise of ctDNA and MRD endpoints, expanded coverage for advanced genomic tests, and an explosion of innovation across digital pathology, spatial omics, multimodal analytics and agentic AI diagnostic platforms, as evidenced by over $60B in diagnostic deal-making and partnerships.
Powered by these tailwinds, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns as the longest standing, end-to-end precision medicine meeting, uniting 850+ senior stakeholders across biopharma, diagnostic, regulatory, healthcare, testing labs and multimodal communities. In 2026, this cornerstone summit expands to five dedicated content tracks, reflecting the complexity and acceleration of novel endpoints and IVD innovation.
This forum is an industry-targeted event with a very specific focus and I appreciate that this has stayed consistent for the precision medicine community over the years
Global Director, Amgen
A great opportunity to network with professionals in the companion diagnostics field and stay informed on the latest trends, emerging technologies and regulatory challenges
Director, Translational Medicine, AstraZeneca
This forum forges the opportunity to 1) meet with a diverse group of individuals and organizations working in the CDx space, 2) hear about ongoing efforts, challenges and wins, 3) connect with key vendors working in the biomarker and CDx space
Head, Translational Medicine, Pfizer
Register Your Interest for 2026
- Free* to Attend for Biopharma & Academia
- The Globally Leading Biomarker & Companion Diagnostic Forum
- Strategic Rx-Dx Co-Development & Partnership Selection Panels
- Biomarker Panels in Oncology, Hematology, Neurological, Chronic, Autoimmune, & Rare Disease
- Brand-New Case Studies on Digital Pathology, Multimodal Data and AI-Enabled Precision Medicine
- Exclusive Networking & Partnerships Opportunities
2026 Faculty Announcements Coming Soon | 2025 Speakers Included
Expertise Partners Include
Explore Related Events
Explore the New Agenda
Hear the latest imaging, multi-omics, single-cell and functional assays, enhanced by AI-driven digital biomarker strategies, enabling earlier and smarter treatment decisions for oncology, autoimmune, neurological, chronic and rare disease patients
Prioritize Partnering with Us
Take up a partnering slot to stand alongside leading biomarker, diagnostic and technology providers, ensure your brand is front and center, and retain your position as the partner of choice in the ever-expanding precision medicine space
Join 850+ Specialist Experts
Be part of the liveliest Rx-Dx conversations with like-minded industry peers spanning a range of precision therapy modalities, and build high-value connections during dedicated networking sessions designed to foster collaborations